New research shows that testing for tumor DNA in the blood can effectively identify advanced bladder cancer patients who will not relapse after surgery. This could lead to more targeted treatments, sparing patients from unnecessary further treatment. Results from the IMvigor011 Phase III trial presented at the European Association of Urology Congress reveal that patients with negative circulating DNA test post-surgery had a low relapse rate. Additionally, patients given immunotherapy after surgery showed improved overall survival rates. These findings could help healthcare practitioners select high-risk patients who will benefit from treatment while sparing others. Further research is needed to determine the long-term benefits of these approaches.
Source link
Bladder cancer treatment can be better targeted and more effective, trials show
